Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4642 plus antitumor therapies in advanced solid tumors with KRAS G12D mutation (Phase Ib/II)
CTR20241407Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-4642 in Nonhematologic neoplasms, sponsored by Hengrui Therapeutics. Started Jul 2024; status: active.
02
Drugs
HRS-4642
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20241407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241407.